The DOI matches its Crossref record, with a small difference in title or year; 100 of the 101 references it cites were found in a registry or an index; 56 of the 77 sources its claims cite were checked for support.
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
Open accessAbstract
The androgen receptor (AR) is a critical driver of prostate cancer (PCa). Here, to study regulators of AR protein levels and oncogenic activity, we developed a live-cell quantitative endogenous AR fluorescent reporter. Leveraging this AR reporter, we performed genome-scale CRISPRi flow cytometry sorting screens to systematically identify genes that modulate AR protein levels. We identified and validated known AR protein regulators, including HOXB13 and GATA2, and also unexpected top hits including PTGES3-a poorly characterized gene in PCa. PTGES3 repression resulted in loss of AR protein, cell-cycle arrest and cell death in AR-driven PCa models. Clinically, analysis of PCa data demonstrates that PTGES3 expression is associated with AR-directed therapy resistance. Mechanistically, we show PTGES3 binds directly to AR, regulates AR protein stability and is necessary for AR function in the nucleus at AR target genes. PTGES3 represents a potential therapeutic target for overcoming known mechanisms of resistance to existing AR-directed therapies in PCa.
Overview
CoChat Summary
## TL;DR
The paper identifies PTGES3 as a direct regulator of androgen receptor (AR) protein levels and AR-dependent transcription in advanced prostate cancer using an endogenous AR fluorescent reporter and genome-scale CRISPRi screens. PTGES3 loss reduces AR protein, impairs AR function, and delays tumor growth, while higher PTGES3 expression is associated with worse clinical outcomes and AR-directed therapy resistance.
## Key findings
- A live-cell endogenous AR mNeonGreen2 reporter was built in C42B prostate cancer cells and used for genome-scale CRISPRi flow-sorting screens; the screen recovered known AR regulators such as HOXB13 and GATA2 and nominated PTGES3 as a top hit.
- PTGES3 repression reduced AR protein in multiple AR-driven models, including C42B, 22RV1, VCaP, and enzalutamide-resistant MR49F cells, and lowered AR splice variant 7 in 22RV1 cells.
- In clinical samples, PTGES3 protein was present in cytosolic and nuclear compartments in a tissue microarray of 120 PCa biopsies; high nuclear PTGES3 was associated with worse PSA-recurrent free survival, with hazard ratio = 2.655 and log-rank P = 0.0014.
- In a cohort of 641 prostatectomy samples, PTGES3 overexpression was associated with significantly worse metastasis-free survival in patients who received adjuvant ADT after prostatectomy, and higher tumor PTGES3 expression was correlated with worse overall survival in mCRPC patients treated with first-line AR-targeted therapy.
## Methods
- The study combined an endogenous AR split-fluorescent reporter with genome-scale CRISPRi screens in two C42BmNG2-AR clonal cell lines; cells were sorted into the top and bottom quartiles of AR fluorescence and sgRNA abundances were sequenced to identify AR regulators.
- Follow-up assays included qPCR, western blotting, co-IP, proximity ligation, luciferase reporter assays, mass spectrometry, ChIP–qPCR/ChIP–seq, ATAC-seq, and in vivo xenograft experiments in male NSG mice with inducible PTGES3 repression.
- Clinical association analyses used a 120-sample prostate tumor tissue microarray and public expression data from 641 prostatectomy samples plus mCRPC cohorts; survival was analyzed with Kaplan–Meier, log-rank tests, and Cox proportional hazards regression.
## Limitations
- The paper states that no statistical methods were used to predetermine sample sizes, and that data distribution was assumed to be normal but not formally tested.
- The text makes evident that several assays were performed in cell-line and mouse models, so direct clinical efficacy of PTGES3 targeting in patients is not established (evident from the study design).
- The text also makes evident that some results are associative in patient cohorts rather than causal, for example the PTGES3 expression-survival analyses (evident from the clinical cohort analyses).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
















Verification
Claims the paper makes
23 Valid · 0 Not valid · 6 Not checked · 91 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
§ Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer > Main
What the sources say
- Partly supportedcites [2] Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758–769 (2018). sourceExperimental — accuracy not yet measured
The Results section (“Duplications target AR, MYC, and FOXA1”; page not provided) identifies AR and upstream-enhancer amplifications associated with increased AR expression. The Discussion links enhancer amplification to resistance following first-line androgen deprivation therapy, but the Results say it was not associated with prior abiraterone or enzalutamide treatment. The paper therefore supports the identification of alterations that increase AR expression, not specifically their emergence during treatment with an ARSI. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [22] Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401–406 (1995). source
- Partly supportedcites [23] Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012). sourceExperimental — accuracy not yet measured
The paper reports aberrations in AR and interacting proteins in heavily pretreated castration-resistant prostate cancer and says androgen signaling can remain active after androgen-deprivation therapy (Abstract; page unavailable). It does not show that these alterations reactivate AR signaling during treatment with an AR signaling inhibitor (ARSI); its tested FOXA1 mutations instead repress androgen signaling. (LLM, conf=0.85)
- Partly supportedcites [24] Takeda, D. Y. et al. A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. Cell 174, 422–432 (2018). sourceExperimental — accuracy not yet measured
The Results section (‘AR enhancer allelic knock-in confers a castration resistant state’; page unavailable) shows that an added AR enhancer copy increased AR expression and reduced sensitivity to enzalutamide, an AR-signaling inhibitor. The paper identifies this alteration in advanced prostate cancer, but the cited passages do not establish that it arose during ARSI treatment in patients. (LLM, conf=0.84)
- Supportedcites [25] Viswanathan, S. R. et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell 174, 433–447 (2018). source
The Results section, “Persistent Selective Pressure on AR and AR Enhancer During Androgen Pathway Inhibition,” reports gains at the AR gene and enhancer loci during progression on enzalutamide and abiraterone. The Discussion states that these elements maintain increased AR expression and activated AR signaling in mCRPC. Page numbers were not provided in our copy. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [26] Gregory, C. W., Johnson, R. T., Mohler, J. L., French, F. S. & Wilson, E. M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61, 2892–2898 (2001).
- Supportedcites [27] Henzler, C. et al. Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat. Commun. 7, 13668 (2016). source
The Abstract identifies AR genomic structural rearrangements as drivers of persistent AR signalling despite second-generation AR-targeted therapies. The Discussion reports that rearrangement-dependent AR variants have enzalutamide-resistant transcriptional activity, supporting the claim that identified tumour alterations can sustain AR signalling under AR-targeted treatment. (LLM, conf=0.90)
- Partly supportedcites [28] Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L. & Tindall, D. J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68, 5469–5477 (2008). sourceExperimental — accuracy not yet measured
The Abstract and Discussion (pages unavailable) identify a novel AR splice variant that is constitutively active and enriched in therapy-resistant prostate cancer xenografts. The paper links this alteration to resistance to androgen ablation, but does not establish that it arose during treatment with a specific AR signaling inhibitor (ARSI). (LLM, conf=0.82)
- Partly supportedcites [29] Chang, K.-H. et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154, 1074–1084 (2013). sourceExperimental — accuracy not yet measured
The Results section reports selection of the HSD3B1(1245C) mutation in abiraterone-treated xenograft tumors and shows that its protein product amplifies androgen-regulated gene expression in a separate model. The Discussion says this suggests a mechanism of abiraterone resistance, but notes that its contribution to clinical resistance remains undetermined; the paper does not directly show AR signaling being reactivated during ARSI treatment. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, aggressive PCa frequently escapes these therapies by reactivating AR signaling19.”
§ Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer > Main
What the sources say
- Supportedcites [19] Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701–711 (2015). source
The Introduction describes progression after hormonal therapy and identifies restored AR signaling as a category of resistance to AR-targeted treatment. The Restored Androgen Receptor Signaling section reports AR mutation or amplification in more than 60% of castration-resistant cases, supporting the claim that this is a frequent escape mechanism. The review also describes other resistance mechanisms; the claim does not say AR reactivation is the only one. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
- Also stated in: § Main · plain
“The androgen receptor (AR) is a central driver of tumorigenesis and disease progression in prostate cancer (PCa)1,2.”
§ Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer > Abstract
What the sources say
- Partly supportedcites [1] Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015). sourceExperimental — accuracy not yet measured
The Results (AR signaling pathway; page unavailable) report AR-pathway alterations in 107 of 150 advanced prostate cancer cases. The Discussion (page unavailable) says this strongly implies that most patients with metastatic castration-resistant prostate cancer remain dependent on AR signaling. That supports AR’s central role in the advanced disease studied, but does not establish the claim for prostate cancer generally. (LLM, conf=0.82)
- Partly supportedcites [2] Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758–769 (2018). sourceExperimental — accuracy not yet measured
The Results (“A landscape of mutations and structural alterations,” page unavailable) report AR-related alterations in 85% of the metastatic castration-resistant prostate cancer samples, supporting AR’s importance in that setting. The claim refers to prostate cancer generally, while this paper’s findings concern its metastatic castration-resistant form. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Main · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent analyses of clinical samples have demonstrated that the vast majority of mCRPC samples from patients resistant to ARSI agents abiraterone and enzalutamide exhibit robust AR/nuclear AR staining20,21.”
§ Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer > Main
What the sources say
- Partly supportedcites [20] Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492–2503 (2018). sourceExperimental — accuracy not yet measured
The Results (page not provided) report strong nuclear AR staining in 90 of 106 tested biopsies (15 of 20 t-SCNC and 75 of 86 adenocarcinoma specimens). They also report that 73% of enrolled patients had progressed on abiraterone and/or enzalutamide, but do not give the staining rate specifically for those patients. The claim extends the overall staining finding to that resistant subgroup. (LLM, conf=0.85)
- Partly supportedcites [21] Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474–489 (2017). sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says resistance to AR-directed therapy is usually accompanied by reactivation of AR signaling. But the Results (page not provided) give the 85% AR-active figure for tumors collected before enzalutamide and abiraterone were approved; they do not establish that the vast majority of samples from patients resistant to those drugs have robust AR or nuclear AR staining. (LLM, conf=0.82)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among them, FKBP4, PTGES3, UBE2I, HOXB13 and GATA2 showed evidence for physical subnetwork interactions with AR37.”
§ Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer > Results > Identification of regulators of AR using a genome-scale CRISPRi screen We next set out to use our C42BmNG2-AR cell lines to identify genes that regulate AR protein abundance. We first stably expressed a dCas9-KRAB fusion CRISPRi construct in C42BmNG2-AR cells. Control experiments targeting TP53 and AR demonstrated CRISPRi gene silencing activity (Extended Data Fig. 2a–c). We next performed genome-scale CRISPRi screens in two C42BmNG2-AR clonal cell lines using fluorescence-activated cell sorting to identify genes whose repression would decrease or increase AR protein levels (Fig. 2a and Extended Data Fig. 2d). Genome-scale pooled genetic screens were performed by transducing C42BmNG2-AR stably expressing dCas9-KRAB (C42BimNG2-AR) with a genome-scale CRISPRi library35. Samples were collected, fixed with 3% paraformaldehyde (PFA), and then sorted to isolate cells in the top and bottom quartile of AR fluorescent signal. We extracted genomic DNA and amplified the sgRNAs present and quantified sgRNA abundance in each sample by quantitative sequencing to identify genes that regulate AR levels. We confirmed that our screening strategy could robustly capture phenotypes induced by repression of genes such as AR or other commonly essential genes that induce strong growth phenotypes when repressed using timecourse fluorescent competition growth assays and by analysis of the abundance of commonly essential and nonessential single-guide RNA (sgRNA) in our CRISPRi genome-scale screening data (Extended Data Fig. 2e,f). We chose to focus solely on genes required for maintenance of AR levels, as such genes, if targetable, would be therapeutically relevant to PCa therapy. As expected, sgRNAs targeting AR were enriched strongly in the low AR screen sample, meaning that repression of AR resulted in the greatest decrease in AR protein levels. We also identified other known AR regulators including HOXB13, GRHL2 and GATA2 as top hits suggesting our screen robustly identifies genes required for AR protein abundance (Fig. 2b). Top hits required for AR abundance include genes involved in chromatin transcription, RNA transportation, transcription factor and post-translation regulation, indicating that numerous biological processes influence AR protein levels. Top gene hits included protein complexes such as PAF and proteins such as HOXB13 and GATA2 known to interact directly or indirectly with AR36 (Fig. 2c). Among them, FKBP4, PTGES3, UBE2I, HOXB13 and GATA2 showed evidence for physical subnetwork interactions with AR37. Several genes known to be regulated transcriptionally by AR were identified as hit genes, suggesting AR protein levels may be regulated by AR target genes, as has been demonstrated previously for select examples such as FKBP438. We validated individual top hit genes including ARID1A, GATA2, GRHL2, HOXB13, PTGES3, FKBP4, SAE1, PAF1, MAP3K19 and CSNK2A1 in two C42BimNG2-AR clonal cell lines demonstrating our screen results were reproducible and identified genes that modulate AR levels (Fig. 2d and Extended Data Fig. 3a). As a control we confirmed by quantitative PCR (qPCR) with reverse transcription (RT–qPCR) that CRISPRi knockdown of top hits decreased the mRNA expression of each targeted hit gene as expected (Extended Data Fig. 3b). To extend our results beyond the C42BimNG2-AR model, we confirmed repression of top hits identified in the screen decreased AR protein levels in parental C42B and LNCaP cells expressing dCas9-KRAB (hereafter C42Bi and LNCaPi), demonstrating the tagged mNG2-AR protein and unmodified AR protein are regulated by the same genes and further confirming the mNG2-AR model as a robust tool for studying AR biology (Fig. 2e and Extended Data Fig. 3c,d). We also validated our screen results using orthogonal genetic and chemical strategies, (ARD-61 for AR, ML-792 for SAE1, siPTGES3 for PTGES3 and CX-4945 for CSNK2A1). In each case, perturbation of candidate genes reduced AR protein levels (Fig. 2f). Our results demonstrate genome-scale fluorescence-activated cell sorting (FACS)-based CRISPRi screens utilizing the C42BmNG2-AR model robustly identified both known and unexpected genes that regulate AR levels.
What the sources say
- Partly supportedcites [37] Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607–D613 (2019). sourceExperimental — accuracy not yet measured
The Introduction describes STRING as a tool for visualizing protein-association networks, which supports its use for a subnetwork analysis. But the Database Content section says STRING associations need not be physical interactions, and our copy does not report interactions between AR and the five named proteins. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
50 more claims · 4 with their cited sources checked
Create a free account to see all 120 claims and every source verdict.
- Probably not a substantial claim. 36
- It may state two separate claims as one. 33
- The quote only partly states this claim. 1
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Self-citationFast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Self-citationFast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Self-citationSzklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749 · cited 1×
“Among them, FKBP4, PTGES3, UBE2I, HOXB13 and GATA2 showed evidence for physical subnetwork interactions with AR 37 .”
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Cited by
Nandakumar, R., Mahin, A., Gopalakrishnan, A. P., Subair, S., Krishnan, D., & Raju, R. (2026) · OMICS A Journal of Integrative Biology · doi:10.1177/15578100261422809 · Cited by 2
“Similarly, the co-chaperone PTGES3 (p23) modulates androgen receptor (AR) stability and has been implicated in resistance to AR-targeted therapies in prostate cancer, as iden-ti fi ed in genome-scale Clustered regularly interspaced short palindromic repeats (CRISPR) screens (Li et al., 2025).”
Mishra, R., Song, S., Choradia, D., Rudoy, D., Wladyka, C. L., Hoang, P., kim, J. Y., Coleman, I. M., Arora, S., Dobersch, S., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci199838 · Cited by 4
“To further narrow down functional posttranslational regulators of AR, we compared our upregulated proteins to a genome-scale CRISPRi screen for positive regulators of AR expression (Supplemental Figure 6G) (44).”
Self-citationA molecular cell atlas of endocrine signaling in human neural organoids
Matassa, G., Rigoli, M. T., Castaldi, D., Valenti, A., Lessi, M., Caporale, N., Stucchi, S., Muda, B., Nagni, R., Mainardi, L., et al. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100077 · Cited by 7
Wang, N., Chen, W., Shen, S., Qi, J., Wang, S., Wang, R., Li, M., Chen, Z., Chen, J., Hong, B., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00431-6 · Cited by 1
“This distinguishes its mode of action from co-regulator roles observed in lung cancer (targeting COX-2 ) [14] or prostate cancer (targeting AR) [27].”
Self-citationAgent-Driven Validation of Oncology Therapeutic TargetsPreprint
Huang, K.-L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.29.721634
Metadata
- Authors
- Li, H., Melnyk, J. E., Fu, B. X. H., Shrestha, R., Zhang, M., Sjöström, M., Feng, S., Anderson, J. A., Han, W., Chesner, L. N., Shin, H. J., Farsh, T., Suarez, H. J., Nath, S., Chou, J., Das, R., Egusa, E. A., Calvert, M., Kishishita, A., Barpanda, A., Zhu, J., Maheshwari, A., Chen, W. S., Alshalalfa, M., Winters, A., Hua, J. T., Liu, T., Davicioni, E., Wiita, A. P., Stohr, B. A., Siddiqui, J., Huang, B., Small, E. J., Shokat, K. M., Nelson, P. S., Quigley, D. A., Wasmuth, E. V., Gilbert, L. A., & Feng, F. Y.
- Affiliations
- University of California, San Francisco (US)
- Emory University (US)
- Fred Hutch Cancer Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Michigan (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Li, Haolong
- Gilbert, Luke A.
- ORCID
- Li, Haolong
- Melnyk, James E.
- Fu, Becky Xu Hua
- Shrestha, Raunak
- Zhang, Meng
- Sjöström, Martin
- Anderson, Jasmine A.
- Han, Wanting
- Chesner, Lisa N.
- Farsh, Tatyanah
- Nath, Seema
- Chou, Jonathan
- Das, Rajdeep
- Egusa, Emily A.
- Kishishita, Audrey
- Barpanda, Abhilash
- Zhu, Jun
- Maheshwari, Ashutosh
- Chen, William S.
- Alshalalfa, Mohammed
- Hua, Junjie T.
- Liu, Tianyi
- Davicioni, Elai
- Wiita, Arun P.
- Stohr, Bradley A.
- Siddiqui, Javed
- Huang, Bo
- Small, Eric J.
- Shokat, Kevan M.
- Nelson, Peter S.
- Quigley, David A.
- Wasmuth, Elizabeth V.
- Gilbert, Luke A.
- Feng, Felix Y.
- Venue
- Nature Genetics
- Published
- 2025-11-05
- Volume
- 57
- Issue
- 12
- Pages
- 3027-3038
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC12695660
- OpenAlex
- W4415913528
- Cited by
- 10
- References
- 95
- Citations by year
- 2026: 10
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Genetics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed Central (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- U.S. Department of Defense (HT94252310462, HT94252410252, W81XWH2010136, W81XWH2210833, W81XWH2110046, W81XWH)
- Howard Hughes Medical Institute
- U.S. Department of Health and Human Services (1R01CA221969-01, R01GM131641, CA230516-02S1, 1F32CA236347-01, CA204602, 1R01CA230516-01, 1R01CA244550, R01GM124334, P50 CA186786, 1R01CA227025)
- Prostate Cancer Foundation (SU2C-AACR-DT0812, P50CA097186, 21CHAL06, P30 CA015704, 17CHAL06, 21YOUN12, CA-097186, PC230420)
- V Foundation for Cancer Research (V2024-016)
- Cancer Prevention and Research Institute of Texas
- Cancerfonden
- Vetenskapsrådet (2018-00382, 2018-)
- Svenska Läkaresällskapet
- National Institutes of Health (1f32ca236347-01, 1s10od016229-01, W81XWH, K99-R00, CA015704, CA-097186, K99/R00 CA204602)
- University of California, San Francisco
- Stand Up To Cancer (SU2C-AACR-DT0812, DT0812)
- National Cancer Institute (CA097186, K99CA204602, R01CA221969, DP2CA239597, R01CA227025, CA015704, K99‐R00, F32 CA236347, R01CA244550, K99/R00 CA204602, R01CA230516, CA186786, R01CA234715, R00CA204602, R01CA266452, R01CA290875, P30CA015704, P50CA097186, P50CA186786, P50CA275741)
- National Institute of General Medical Sciences (R01GM124334, P41GM103481, R00GM140264, R01GM131641)
- Department of Medicine, University of California, San Francisco
- DOD Prostate Cancer Research Program
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- PTGES3, androgen receptor, advanced prostate cancer, CRISPRi screen, cell cycle arrest, cell death, therapeutic target, HOXB13, GATA2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer. https://app.cochat.ai/papers/10.1038/s41588-025-02388-8
- The paper
- Li, H., Melnyk, J. E., Fu, B. X. H., Shrestha, R., Zhang, M., Sjöström, M., Feng, S., Anderson, J. A., Han, W., Chesner, L. N., Shin, H. J., Farsh, T., Suarez, H. J., Nath, S., Chou, J., Das, R., Egusa, E. A., Calvert, M., Kishishita, A., . . . Feng, F. Y. (2025). Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer. Nature Genetics. https://doi.org/10.1038/s41588-025-02388-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.